-
Mashup Score: 41
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy. A statistically significant and clinically meaningful improvement in PFS
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Rita Nanda, MD, discusses the evolution of treatment with CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Tumor-Infiltrating Lymphocytes as a Prognostic Factor in Triple-Negative Breast Cancer - 5 day(s) ago
High levels of tumor-infiltrating lymphocytes (TILs) have long been thought to reflect an intact antitumor immune response. Higher TIL levels have been
Source: www.jwatch.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 4Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases - 6 day(s) ago
Anne P. O’Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and prognosis.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17MBC Impact Series: Metastatic Inflammatory Breast Cancer - 7 day(s) ago
Watch this previously recorded webinar to hear about the latest treatments and research on inflammatory breast cancer from Dr. Wendy Woodward of MD Anderson.
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Positive results from Destiny B06: T-DXd demonstrated PFS improvement over chemotherapy in the primary and overall trial population (incl HER2-low and ultralow). #bcsm @oncoalert https://t.co/giUoNyFNbu